NRBO READ THE FULL NRBO RESEARCH REPORT Business Update   Topline Results from Phase 2a Trial of DA-1241 in MASH Expected in ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously ...

About the NVG-291 Phase 1b/2a Trial The double-blind ... NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting nervous system repair. NVG-291's technology ...

ClearPoint Neuro reported strong YoY growth in Q3, but the stock reacted negatively. Check out my recommendation for CLPT ...

Study DUS-AUBD-01 opens patient enrollment PRINCETON, N.J., Nov. 14, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage ...

Bicycle's bicyclic peptide drug discovery platform is designed ... a cell-killing payload – which is being tested in a phase 1/2a trial in solid tumours sponsored by CRUK. Following after ...

Clarity announced in August that its phase 1/2a trial in paediatric patients with ... of tumour targets than small molecules or small peptides. Importantly, the three-dimensional shape of the ...

Neurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, United States This important study employed multiple orthogonal techniques and ...

DWTX READ THE FULL DWTX RESEARCH REPORT Business Update Phase 2 Long COVID Results Expected Soon Dogwood Therapeutics, Inc.

This study presents a valuable finding on the molecular mechanisms that govern GABAergic inhibitory synapse function. The authors propose that Endophilin A1 serves as a novel regulator of GABAergic ...

BOLSTER: Phase 2a double-blind, placebo-controlled, multi-center, randomized trial in the U.S. evaluating certepetide in combination with SoC in first- and second-line cholangiocarcinoma (“CCA”). The ...